Although the vaccine produced an increased expression of PD-L1 that reactivates the tumor, the sequential administration of the nanovaccine and their combination with an anti-PD-1 checkpoint inhibitor suppressed the reappearance of cancer cells in the animals [37]. This evidence concerns the gene CD274 and neoplasm.